2. NF-κB Immunology/Inflammation Apoptosis Autophagy Cell Cycle/DNA Damage MAPK/ERK Pathway
  3. NF-κB COX Apoptosis Autophagy NO Synthase PERK JNK p38 MAPK CDK NOD-like Receptor (NLR)
  4. Dehydrodiisoeugenol

Dehydrodiisoeugenol is an orally active anti-inflammatory and anti-tumor agent. Dehydrodiisoeugenol inhibits the proliferation of colorectal cancer cells, and induces apoptosis, autophagy, endoplasmic reticulum stress and cell cycle arrest. Dehydrodiisoeugenol also exerts anti-inflammatory effects by inhibiting the activation of NF-κB and the expression of COX-2. Dehydrodiisoeugenol can be used in the research related to colorectal cancer, inflammatory diseases and ulcerative colitis.

For research use only. We do not sell to patients.

CAS No. : 2680-81-1

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
1 mg In-stock
5 mg In-stock
10 mg In-stock
20 mg In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 4 publication(s) in Google Scholar

Other Forms of Dehydrodiisoeugenol:

Dehydrodiisoeugenol Related Antibodies

Top Publications Citing Use of Products
Cell Proliferation/Viability Assay
WB
Histological Imaging/Staining
Flow Cytometry
ELISA

    Dehydrodiisoeugenol purchased from MedChemExpress. Usage Cited in: Mol Med. 2025 Jun 5;31(1):221.  [Abstract]

    The CCK-8 assay to determine the cell viability of LPS (0.5 µg/ml)/IFNγ (10ng/ml) stimulated RAW264.7 cells treated with different concentration of Dehydrodiisoeugenol (DEH) (0.5, 1, 2, 4, 8, 10, 20 μM) or Curcumin (5µM).

    Dehydrodiisoeugenol purchased from MedChemExpress. Usage Cited in: Mol Med. 2025 Jun 5;31(1):221.  [Abstract]

    Western blotting analysis of iNOS and COX2 protein expression in RAW264.7 cells treated with different concentrations of Dehydrodiisoeugenol (DEH) (2.5, 5, 10 μM) or curcumin (5 µM) following LPS/IFNγ stimulation.

    Dehydrodiisoeugenol purchased from MedChemExpress. Usage Cited in: Mol Med. 2025 Jun 5;31(1):221.  [Abstract]

    Apply the HE staining method to detect the effects of Dehydrodiisoeugenol (DEH) (40 mg/kg) or an equivalent solvent gastric lavage on the nude mouse xenografts.

    Dehydrodiisoeugenol purchased from MedChemExpress. Usage Cited in: Mol Med. 2025 Jun 5;31(1):221.  [Abstract]

    Flow cytometry was used to detect apoptosis in the cells. HCT116 cells were treated with Dehydrodiisoeugenol (DEH) (20 µM, 40 µM) for 24 h.

    Dehydrodiisoeugenol purchased from MedChemExpress. Usage Cited in: Mol Med. 2025 Jun 5;31(1):221.  [Abstract]

    ELISA was used to measure the expression levels of MPO, IL-1β, TNF-α, and IL-6 treated with Dehydrodiisoeugenol (DEH) (5, 10, 20 mg/kg, i.g.).

    View All NF-κB Isoform Specific Products:

    View All Isoforms
    NF-κB NF-κB1/p50 RelA/p65 RelB c-Rel

    View All COX Isoform Specific Products:

    View All Isoforms
    COX COX-1 COX-2 COX-3

    View All NO Synthase Isoform Specific Products:

    View All Isoforms
    nNOS iNOS eNOS

    View All JNK Isoform Specific Products:

    View All Isoforms
    JNK1 JNK2 JNK3 JNK

    View All p38 MAPK Isoform Specific Products:

    View All Isoforms
    p38 MAPK Akt1 p38α p38β MAPK13 p38δ p38γ

    View All CDK Isoform Specific Products:

    View All Isoforms
    CDK1 CDK2 CDK3 CDK4 CDK5 CDK6 CDK7 CDK8 CDK9 CDK11 CDK12 CDK13 CDK14 CDK16 CDK19 CDC CLK Pho85 CDK10 CDK15 CDK17 CDK18 CDK20 PITSLRE

    View All NOD-like Receptor (NLR) Isoform Specific Products:

    View All Isoforms
    NLRP3 NLRP1 NOD1 NOD2

    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Dehydrodiisoeugenol is an orally active anti-inflammatory and anti-tumor agent. Dehydrodiisoeugenol inhibits the proliferation of colorectal cancer cells, and induces apoptosis, autophagy, endoplasmic reticulum stress and cell cycle arrest. Dehydrodiisoeugenol also exerts anti-inflammatory effects by inhibiting the activation of NF-κB and the expression of COX-2. Dehydrodiisoeugenol can be used in the research related to colorectal cancer, inflammatory diseases and ulcerative colitis[1][2][3].

    IC50 & Target

    NF-κB; COX-2[2]
    In Vitro

    Dehydrodiisoeugenol (0.001-1000 μM; 24-72 h) inhibits the viability of human colorectal cancer HCT 116 and SW620 cells in a time- and dose-dependent manner, with IC50 values of 54.32 μM and 46.74 μM respectively after 48 h of treatment, and exerts weak inhibitory effects on the viability of normal human colonic epithelial NCM460 cells[1].
    Dehydrodiisoeugenol (20-60 μM; 48 h) reduces the self-renewal and colony-forming capacities of human colorectal cancer HCT 116 and SW620 cells, and induces cell cycle arrest, autophagy and endoplasmic reticulum stress[1].
    Dehydrodiisoeugenol (0.1-10 μM; 3.5-6.5 h) potently inhibits LPS (HY-D1056)-induced COX-2 expression in RAW264.7 mouse macrophages without affecting the expression of constitutive COX-1[2].
    Dehydrodiisoeugenol (0.1 μM; 1 h) inhibits LPS-induced, phosphorylation-dependent IκB-α proteolysis in RAW264.7 mouse macrophages[2].
    Dehydrodiisoeugenol (0.1 μM; 6.5 h) inhibits the transcriptional activity of NF-κB in LPS-stimulated RAW264.7 mouse macrophages[2].
    Dehydrodiisoeugenol (2.5-10 μM; 24 h) inhibits the production of NO and PGE2, the expression of iNOS, COX2 and NOD2, and the activation of MAPK and NF-κB pathways in RAW264.7 macrophages stimulated by LPS/IFNγ[3].
    Dehydrodiisoeugenol (20-40 μM; 0-10 days) inhibits colony formation and proliferation of HCT116 colorectal cancer cells, and induces apoptosis, autophagy and cell cycle arrest[3].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Dehydrodiisoeugenol Related Antibodies

    Cell Viability Assay[1]

    Cell Line: human colorectal cancer cell lines HCT 116, SW620; normal human colon epithelial cell NCM460
    Concentration: 0.001, 0.01, 0.1, 1, 10, 20, 40, 60, 80, 100, 125, and 1000 μM
    Incubation Time: 24 h, 48 h, 72 h
    Result: Inhibited cell viability in a time- and dose-dependent manner in HCT 116 and SW620 cells.
    Showed significantly higher IC50 for normal NCM460 cells than colorectal cancer cell lines.

    Western Blot Analysis[1]

    Cell Line: human colorectal cancer cell lines HCT 116, SW620
    Concentration: 20, 40 and 60 μM
    Incubation Time: 0 h, 12 h, 24 h, 48 h
    Result: Significantly increased the expression of p21 protein in a dose- and time-dependent manner.
    Significantly reduced the expression of CDK2, CDK4, Cyclin D1, Cyclin E1, and Cyclin E2 proteins in a dose- and time-dependent manner.

    Western Blot Analysis[1]

    Cell Line: human colorectal cancer cell lines HCT 116, SW620
    Concentration: 20, 40 amd 60 μM
    Incubation Time: 48 h
    Result: Upregulated the expression of LC3B-II, ATG7, and p62 proteins in a dose-dependent manner.\n
    Upregulated the expression of BiP, Ero1-Lα, PERK, p-eIF2α, IRE1α, XBP-1s, and CHOP proteins in a dose-dependent manner.

    Western Blot Analysis[1]

    Cell Line: human colorectal cancer cell lines HCT 116, SW620
    Concentration: 60 μM (48 h; 6 h for EBSS co-treatment)
    Incubation Time: 6 h, 48 h
    Result: Reduced LC3B-II levels when co-treated with 3-MA compared to DEH alone. Did not cause a further increase in LC3B-II levels when co-treated with CQ or Baf A1 compared to DEH alone.

    Western Blot Analysis[2]

    Cell Line: RAW264.7 murine macrophages
    Concentration: 0.1 μM
    Incubation Time: 30 min pre-incubation, followed by 30 min LPS stimulation
    Result: Significantly inhibited LPS-stimulated phosphorylation of IκB-α.
    Prevented LPS-induced degradation of total IκB-α protein.

    Western Blot Analysis[3]

    Cell Line: LPS/IFNγ-stimulated RAW264.7 macrophages
    Concentration: 2.5, 5 and 10 μM
    Incubation Time: 24 h
    Result: Significantly inhibited the expression of iNOS and COX2, with the most pronounced effect at 10 μM.
    Inhibited the phosphorylation of IKKα/β and IκBα at 5 and 10 μM.
    Inhibited IκBα degradation and NF-κB p65 nuclear translocation at 10 μM.
    Significantly inhibited the phosphorylation of ERK, JNK, and p38 at 2.5, 5, and 10 μM.
    In Vivo

    Dehydrodiisoeugenol (40 mg/kg; i.p.; once every other day; 2 weeks) significantly inhibits colorectal cancer tumor growth in mouse CDX and PDX models, reduces tumor cell proliferation, induces ER stress and alters autophagy signaling pathways, and exhibits low toxicity in mice[1].
    Dehydrodiisoeugenol (5-20 mg/kg; i.g.; once daily; for 8 days) dose-dependently ameliorates DSS (HY-116282C)-induced ulcerative colitis in BALB/c mice by alleviating intestinal inflammation, restoring barrier function, and inhibiting NOD2 expression[3].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: NOD/SCID (5-week-old female)[1]
    Dosage: 40 mg/kg
    Administration: i.p.; once every other day; 2 weeks
    Result: Significantly reduced tumor volume in HCT 116, SW620, and PDX xenograft models relative to controls.
    Significantly reduced the percentage of Ki67-positive cells (cell proliferation marker) in tumor tissues relative to controls.
    Significantly upregulated expression of ER stress-related proteins (BiP, PERK, IRE1α) and autophagy-related proteins (LC3B-II, p62) in harvested tumors relative to controls.
    Showed no significant changes in mouse body weight, and H&E staining of heart, liver, spleen, lung, and kidney tissue revealed no pathological abnormalities indicative of toxicity.
    Animal Model: BALB/c (male, 6-8 weeks old, 20-22 g, ulcerative colitis model via 3.5% DSS gavage)[3]
    Dosage: 5 mg/kg; 10 mg/kg; 20 mg/kg
    Administration: p.o.; daily; 8 days
    Result: Significantly increased mouse body weight and colon length compared to the DSS model group.\n
    Dose-dependently reduced colon mucosal damage, edema, and inflammatory cell infiltration, with partial recovery of goblet cells and crypts.
    Significantly restored colonic ZO-1 and Occludin protein expression at 20 mg/kg to improve intestinal barrier function.\n
    Dose-dependently significantly reduced colon MPO levels and serum TNF-α, IL-6, and IL-1β levels.
    Significantly reduced colonic NOD2 protein expression at 10 mg/kg and 20 mg/kg.
    Molecular Weight

    326.39

    Formula

    C20H22O4
    CAS No.
    Appearance

    Solid

    Color

    White to off-white

    SMILES

    OC1=CC=C(C2OC3=C(OC)C=C(/C=C/C)C=C3C2C)C=C1OC
    Structure Classification
    Initial Source
    Shipping

    Room temperature in continental US; may vary elsewhere.
    Storage
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 6 months
    -20°C 1 month
    Solvent & Solubility
    In Vitro: 

    DMSO : 100 mg/mL (306.38 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 3.0638 mL 15.3191 mL 30.6382 mL
    5 mM 0.6128 mL 3.0638 mL 6.1276 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.08 mg/mL (6.37 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 2.08 mg/mL (6.37 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

      Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    Purity & Documentation

    Purity: 99.98%

    SDS (393 KB)

    COA (246 KB) LCMS (93 KB)

    Handling Instructions (2659 KB)
    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 3.0638 mL 15.3191 mL 30.6382 mL 76.5955 mL
    5 mM 0.6128 mL 3.0638 mL 6.1276 mL 15.3191 mL
    10 mM 0.3064 mL 1.5319 mL 3.0638 mL 7.6595 mL
    15 mM 0.2043 mL 1.0213 mL 2.0425 mL 5.1064 mL
    20 mM 0.1532 mL 0.7660 mL 1.5319 mL 3.8298 mL
    25 mM 0.1226 mL 0.6128 mL 1.2255 mL 3.0638 mL
    30 mM 0.1021 mL 0.5106 mL 1.0213 mL 2.5532 mL
    40 mM 0.0766 mL 0.3830 mL 0.7660 mL 1.9149 mL
    50 mM 0.0613 mL 0.3064 mL 0.6128 mL 1.5319 mL
    60 mM 0.0511 mL 0.2553 mL 0.5106 mL 1.2766 mL
    80 mM 0.0383 mL 0.1915 mL 0.3830 mL 0.9574 mL
    100 mM 0.0306 mL 0.1532 mL 0.3064 mL 0.7660 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Dehydrodiisoeugenol Related Classifications

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Dehydrodiisoeugenol2680-81-1NF-κBCOXApoptosisAutophagyNO SynthasePERKJNKp38 MAPKCDKNOD-like Receptor (NLR)Nuclear factor-κBNuclear factor-kappaBCyclooxygenaseNitric oxide synthasesNOSProtein kinase R-like endoplasmic reticulum kinasePKR-like endoplasmic reticulum kinasec-Jun N-terminal kinaseCyclin dependent kinasecolorectal cancerHCT 116 cellsSW620 cellsulcerative colitisInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Requested Quantity *

    Applicant Name *

    		 

    Salutation

    Email Address *

    		 

    Phone Number *

    Department

    		 

    Organization Name *

    City

    State

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Dehydrodiisoeugenol
    Cat. No.:
    HY-N0589
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    SAFETY DATA SHEET (SDS)

    English - EN (393 KB) Français - FR (393 KB) Deutsch - DE (393 KB) Norwegian - NO (393 KB) Español - ES (393 KB) Swedish - SV (393 KB) Italian - IT (393 KB) Korean - KR (393 KB) Portuguese - PT (393 KB)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.